Clinical features of CD4+ T-LGL leukemia patients
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . | Patient 10 . | Patient 11 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STAT5b mutation (% VAF) | Q706L (45) | S715F (36) | N642H (25) | N642H (46) | Y665F (31) | N642H (27) | None | None | None | None | None |
| Vbeta expansion (CD4+ population) | Vb.13.1: 98% | Vb.8: 86% | NA | NA | NA | NA | Vb.13.1: 78% | NA | NA | NA | NA |
| Age (years) | 61 | 70 | 74 | 79 | 82 | 66 | 80 | 67 | 58 | 70 | 79 |
| Sex | M | F | M | F | M | M | F | F | F | F | F |
| WBC count (109/L) | 8.5 | 10.2 | 9.0 | 8.7 | 13.9 | 9.4 | 8.7 | 6.8 | 5.5 | 6.1 | 8.2 |
| Neutrophil (%)* | 40 | 16 | 12 | 5 | 51 | 32 | 33 | 35 | 32 | 42 | 26 |
| LGL (%)* | 52 | 72 | 71 | 91 | 39 | 63 | 57 | 44 | 54 | 55 | 69 |
| Hb (g/L) | 134 | 124 | 119 | 126 | 155 | 141 | 135 | 142 | 73 | 135 | 120 |
| Platelets (109/L) | 399 | 204 | 144 | 186 | 245 | 265 | 241 | 143 | 200 | 229 | 156 |
| Other neoplasias | None | None | None | None | None | None | None | None | None | None | None |
| Other diseases | Diabetes | None | None | Gastrointestinal hemorrhage | None | Lung cancer | Osteoarthritis, hypothyroidism | None | None | None | None |
| Observation period | 5 years | 7 years | 14 years | 6 months | 3 years | 2 years | 3 years | 12 years | 6 years | 12 years | 15 months |
| Outcome | Alive | Alive | Death | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Alive |
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . | Patient 10 . | Patient 11 . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STAT5b mutation (% VAF) | Q706L (45) | S715F (36) | N642H (25) | N642H (46) | Y665F (31) | N642H (27) | None | None | None | None | None |
| Vbeta expansion (CD4+ population) | Vb.13.1: 98% | Vb.8: 86% | NA | NA | NA | NA | Vb.13.1: 78% | NA | NA | NA | NA |
| Age (years) | 61 | 70 | 74 | 79 | 82 | 66 | 80 | 67 | 58 | 70 | 79 |
| Sex | M | F | M | F | M | M | F | F | F | F | F |
| WBC count (109/L) | 8.5 | 10.2 | 9.0 | 8.7 | 13.9 | 9.4 | 8.7 | 6.8 | 5.5 | 6.1 | 8.2 |
| Neutrophil (%)* | 40 | 16 | 12 | 5 | 51 | 32 | 33 | 35 | 32 | 42 | 26 |
| LGL (%)* | 52 | 72 | 71 | 91 | 39 | 63 | 57 | 44 | 54 | 55 | 69 |
| Hb (g/L) | 134 | 124 | 119 | 126 | 155 | 141 | 135 | 142 | 73 | 135 | 120 |
| Platelets (109/L) | 399 | 204 | 144 | 186 | 245 | 265 | 241 | 143 | 200 | 229 | 156 |
| Other neoplasias | None | None | None | None | None | None | None | None | None | None | None |
| Other diseases | Diabetes | None | None | Gastrointestinal hemorrhage | None | Lung cancer | Osteoarthritis, hypothyroidism | None | None | None | None |
| Observation period | 5 years | 7 years | 14 years | 6 months | 3 years | 2 years | 3 years | 12 years | 6 years | 12 years | 15 months |
| Outcome | Alive | Alive | Death | Alive | Alive | Alive | Alive | Alive | Alive | Alive | Alive |
F, female; Hb, hemoglobin; LGL, large granular lymphocyte; M, male; VAF, variant allele frequency; WBC, white blood cell.
Neutrophil and LGL percentage from whole white blood cell population. From patients 1, 2, and 3, germline DNA was available for sequencing to confirm the somatic nature of the STAT5b mutations.